Histamine H3 Receptor Antagonists

Cytochrome P450 3A4 Inducers

Histamine H3 Receptor Inverse Agonists

Histamine-3 Receptor Antagonist/Inverse Agonist

Sleep Wake Disorders

<section class="Section" data-sectioncode="34089-3"><a name="s_1100"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">WAKIX tablets contain pitolisant hydrochloride. Pitolisant is an antagonist/inverse agonist of the histamine-3 (H3) receptor. Pitolisant hydrochloride is a white or almost white crystalline powder with a molecular formula of C<span class="Sub">17</span>H<span class="Sub">26</span>ClNO·HCl and a molecular weight of 332.31. Pitolisant hydrochloride is soluble in water, ethanol, and methylene chloride and practically insoluble in cyclohexane. The chemical name of pitolisant hydrochloride is 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride and its structural formula is:</p><p><img alt="chemical structure" src="wakix-01.jpg"/></p><p>The molecular formula of the pitolisant free base is C<span class="Sub">17</span>H<span class="Sub">26</span>ClNO and its molecular weight is 295.85.</p><p>WAKIX tablets are for oral administration and each film-coated tablet contains 5 mg or 20 mg of pitolisant hydrochloride (equivalent to 4.45 mg or 17.8 mg of pitolisant free base, respectively) and the following inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</p></section>

Wakix

pitolisant

pitolisant 4.45 MG Oral Tablet

pitolisant 4.45 MG Oral Tablet [Wakix]

pitolisant 17.8 MG Oral Tablet

pitolisant 17.8 MG Oral Tablet [Wakix]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program 

Wakix Prescription Referral Form

Other HCP Resources 

About Wakix 

Taking Wakix 

Patient Stories 

Wakix For You Support Program 

What To Expect When Taking Wakix 

FAQs: EDS & Cataplexy

Patient Resources 

Instructions For Use: Excessive Daytime Sleepiness (EDS) with Narcolepsy

Instructions For Use: Cataplexy with Narcolepsy 

Starting and Staying on Track With Wakix 

Wakix Patient Brochure 

Tips for Living With Narcolepsy

Starting and Staying on Track With Wakix - Spanish

Wakix Patient Brochure - Spanish

Doctor Discussion Guide

Measuring Your Excessive Daytime Sleepiness (EDS) 

Measuring Your Excessive Daytime Sleepiness (EDS) - Spanish

Understanding Your Cataplexy

Understanding Your Cataplexy - Spanish